In the last decade, anti-CD19 CAR-T cell therapy has led to a treatment paradigm shift for B-cell non-Hodgkin lymphomas, first with the approval for relapsed/refractory (R/R) large B-cell lymphomas and subsequently for R/R mantle cell and follicular lymphoma. Many efforts are continuously being made to extend the therapeutic setting in the lymphoma field. Several reports are supporting the safety and efficacy of CAR-T cells in patients with central nervous system disease involvement. Anti-CD30 CAR-T cells for the treatment of Hodgkin lymphoma are in development and early studies looking for the optimal target for T-cell malignancies are ongoing. Anti-CD19/CD20 and CD19/CD22 dual targeting CAR-T cells are under investigation in order to increase anti-lymphoma activity and overcome tumor immune escape. Allogeneic CAR product engineering is on the way, representing a rapidly accessible ‘off-the-shelf’ and potentially more fit product. In the present manuscript, we will focus on recent advances in CAR-T cell therapy for lymphomas, including new settings and future perspectives in the field, reviewing data reported in literature in the last decade up to October 2023.
过去十年间，抗CD19 CAR-T细胞疗法引领了B细胞非霍奇金淋巴瘤治疗范式的变革，其应用率先在复发/难治性大B细胞淋巴瘤获得批准，随后扩展至复发/难治性套细胞淋巴瘤与滤泡性淋巴瘤。当前淋巴瘤领域正持续推进治疗场景的拓展，多项研究证实CAR-T细胞对中枢神经系统受累患者具有安全性与有效性。针对霍奇金淋巴瘤的抗CD30 CAR-T细胞疗法正在研发中，针对T细胞恶性肿瘤最佳靶点的早期探索也在持续进行。为增强抗淋巴瘤活性并克服肿瘤免疫逃逸，抗CD19/CD20与CD19/CD22双靶点CAR-T细胞的相关研究正在开展。异体CAR产品工程化进程持续推进，有望实现快速可及的"现货型"治疗并可能获得更具适应性的产品。本文聚焦淋巴瘤CAR-T细胞疗法的最新进展，通过系统综述2013年至2023年10月间的文献数据，探讨该领域的新应用场景与未来发展方向。
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions
肿瘤(癌症)患者之家